CTNM Contineum Therapeutics, Inc.
$9.13▼ -2.17%
Healthcare
Other
Volume 112.0K
Avg Volume (10D) 933.3K
Key Metrics & Fundamentals
Market Cap
$343.41M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.73 - 17.79
% vs 50 MA
-27.31%
% vs 200 MA
-31.22%
RSI-14
42.5
MACD Histogram
+0.2200
Beta (1Y vs SPY)
1.43
Free Cash Flow
-$11.51M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$17.29M
COGS
–
Operating Exp
$17.43M
Operating Income
-$17.43M
EBIT
-$17.43M
Pretax Income
-$15.15M
Net Income
-$15.15M
EPS (Diluted)
-0.40
Price & Volume History
Loading chart…
Recent News
Contineum Therapeutics to Present at the Stifel 2026 Healthcare Conference
Business Wire · Oct 29, 2026 4:05 PM ET
BMY Reports Mixed Phase III Trial Results, Stock Down
Zacks · Oct 13, 2026 12:40 PM ET
Baird Downgrades Contineum Therapeutics to Neutral From Outperform, Price Target is $14
MT Newswires · Oct 13, 2026 10:03 AM ET
Bristol Myers Reverses Lower Despite Double Phase 3 Win, As A Key Rival Crashes
Investor's Business Daily · Oct 12, 2026 4:14 PM ET
Bristol Myers Stock Tumbles on ‘Confounding’ Trial Results
Barrons.com · Oct 12, 2026 2:46 PM ET
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Zacks · Oct 12, 2026 11:00 AM ET
Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
InvestorsHub · Oct 12, 2026 8:42 AM ET
Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating
Investing.com · Oct 12, 2026 7:55 AM ET
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
BioPharma Dive · Sep 30, 2026 12:22 PM ET
J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?
Insider Monkey · Sep 24, 2026 7:04 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See CTNM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.